Sodium tetradecyl sulfate: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 1: Line 1:
{{DrugProjectFormSinglePage
{{DrugProjectFormSinglePage
|authorTag=<!--Overview-->
|authorTag=<!--Overview-->{{RB}}
|genericName=Sodium tetradecyl sulfate
|aOrAn=a
|aOrAn=a
|drugClass=sclerosing Agent
|indicationType=treatment
|indicationType=treatment
|hasBlackBoxWarning=Yes
|indication=small uncomplicated varicose veins of the lower extremities
|adverseReactions=<!--Black Box Warning-->
|adverseReactions=Local reactions consisting of pain, urticaria or ulceration, Allergic reactions
 
<!--Black Box Warning-->
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>


* Content
 


<!--Adult Indications and Dosage-->
<!--Adult Indications and Dosage-->


<!--FDA-Labeled Indications and Dosage (Adult)-->
<!--FDA-Labeled Indications and Dosage (Adult)-->
|fdaLIADAdult======Condition1=====
|fdaLIADAdult=====Indications====
 
* Sotradecol (sodium tetradecyl sulfate injection) is indicated in the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves. The benefit-to-risk ratio should be considered in selected patients who are great surgical risks.
* Dosing Information
 
:* Dosage


=====Condition2=====
====Dosage====
* Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use if precipitated or discolored.


* Dosing Information
Sotradecol (sodium tetradecyl sulfate injection) is for intravenous use only. The strength of solution required depends on the size and degree of varicosity. In general, the 1% solution will be found most useful with the 3% solution preferred for larger varicosities. The dosage should be kept small, using 0.5 mL to 2 mL (preferably 1 mL maximum) for each injection, and the maximum single treatment should not exceed 10 mL.
 
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
:* Dosage
 
=====Condition3=====
 
* Dosing Information
 
:* Dosage
 
=====Condition4=====
 
* Dosing Information
 
:* Dosage
 
<!--Off-Label Use and Dosage (Adult)-->
 
<!--Guideline-Supported Use (Adult)-->
|offLabelAdultGuideSupport======Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.


<!--Non–Guideline-Supported Use (Adult)-->
<!--Non–Guideline-Supported Use (Adult)-->
|offLabelAdultNoGuideSupport======Condition1=====
|offLabelAdultNoGuideSupport=* Esophageal varices<ref name="pmid9099596">{{cite journal| author=Iwase H, Kusugami K| title=Symposium on endoscopic hemostasis in gastric diseases. 2. Choice of endoscopic therapy for esophagogastric varices: aiming for safer and more effective therapy. | journal=Intern Med | year= 1997 | volume= 36 | issue= 2 | pages= 128-9 | pmid=9099596 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9099596  }} </ref>
 
* Hemangioma<ref name="pmid3343573">{{cite journal| author=Anavi Y, Har-El G, Mintz S| title=The treatment of facial haemangioma by percutaneous injections of sodium tetradecyl sulfate. | journal=J Laryngol Otol | year= 1988 | volume= 102 | issue= 1 | pages= 87-90 | pmid=3343573 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3343573  }} </ref><ref name="pmid3823245">{{cite journal| author=Woods JE| title=Extended use of sodium tetradecyl sulfate in treatment of hemangiomas and other related conditions. | journal=Plast Reconstr Surg | year= 1987 | volume= 79 | issue= 4 | pages= 542-9 | pmid=3823245 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3823245  }} </ref>
* Dosing Information
|fdaLIADPed=There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
<!--Pediatric Indications and Dosage-->
 
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
|fdaLIADPed======Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.


<!--Off-Label Use and Dosage (Pediatric)-->
<!--Off-Label Use and Dosage (Pediatric)-->


<!--Guideline-Supported Use (Pediatric)-->
<!--Guideline-Supported Use (Pediatric)-->
|offLabelPedGuideSupport======Condition1=====
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.


<!--Non–Guideline-Supported Use (Pediatric)-->
<!--Non–Guideline-Supported Use (Pediatric)-->
|offLabelPedNoGuideSupport======Condition1=====
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.


<!--Contraindications-->
<!--Contraindications-->

Revision as of 16:02, 19 February 2015

Sodium tetradecyl sulfate
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rabin Bista, M.B.B.S. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Sodium tetradecyl sulfate is a sclerosing Agent that is FDA approved for the treatment of small uncomplicated varicose veins of the lower extremities. Common adverse reactions include Local reactions consisting of pain, urticaria or ulceration, Allergic reactions.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Indications

  • Sotradecol (sodium tetradecyl sulfate injection) is indicated in the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves. The benefit-to-risk ratio should be considered in selected patients who are great surgical risks.

Dosage

  • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use if precipitated or discolored.

Sotradecol (sodium tetradecyl sulfate injection) is for intravenous use only. The strength of solution required depends on the size and degree of varicosity. In general, the 1% solution will be found most useful with the 3% solution preferred for larger varicosities. The dosage should be kept small, using 0.5 mL to 2 mL (preferably 1 mL maximum) for each injection, and the maximum single treatment should not exceed 10 mL.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Sodium tetradecyl sulfate in adult patients.

Non–Guideline-Supported Use

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding FDA-Labeled Use of Sodium tetradecyl sulfate in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Sodium tetradecyl sulfate in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Sodium tetradecyl sulfate in pediatric patients.

Contraindications

  • Condition1

Warnings

  • Description

Precautions

  • Description

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Sodium tetradecyl sulfate in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Sodium tetradecyl sulfate in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Drug Interactions

  • Drug
  • Description

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • Pregnancy Category


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Sodium tetradecyl sulfate in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Sodium tetradecyl sulfate during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Sodium tetradecyl sulfate with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Sodium tetradecyl sulfate with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Sodium tetradecyl sulfate with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Sodium tetradecyl sulfate with respect to specific gender populations.

Race

There is no FDA guidance on the use of Sodium tetradecyl sulfate with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Sodium tetradecyl sulfate in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Sodium tetradecyl sulfate in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Sodium tetradecyl sulfate in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Sodium tetradecyl sulfate in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Oral
  • Intravenous

Monitoring

There is limited information regarding Monitoring of Sodium tetradecyl sulfate in the drug label.

  • Description

IV Compatibility

There is limited information regarding IV Compatibility of Sodium tetradecyl sulfate in the drug label.

Overdosage

Acute Overdose

Signs and Symptoms

  • Description

Management

  • Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Sodium tetradecyl sulfate in the drug label.

Pharmacology

There is limited information regarding Sodium tetradecyl sulfate Pharmacology in the drug label.

Mechanism of Action

Structure

File:Sodium tetradecyl sulfate01.png
This image is provided by the National Library of Medicine.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Sodium tetradecyl sulfate in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Sodium tetradecyl sulfate in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Sodium tetradecyl sulfate in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Sodium tetradecyl sulfate in the drug label.

How Supplied

Storage

There is limited information regarding Sodium tetradecyl sulfate Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Sodium tetradecyl sulfate |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Sodium tetradecyl sulfate |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Sodium tetradecyl sulfate in the drug label.

Precautions with Alcohol

  • Alcohol-Sodium tetradecyl sulfate interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Look-Alike Drug Names

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. ↑ Iwase H, Kusugami K (1997). "Symposium on endoscopic hemostasis in gastric diseases. 2. Choice of endoscopic therapy for esophagogastric varices: aiming for safer and more effective therapy". Intern Med. 36 (2): 128–9. PMID 9099596.
  2. ↑ Anavi Y, Har-El G, Mintz S (1988). "The treatment of facial haemangioma by percutaneous injections of sodium tetradecyl sulfate". J Laryngol Otol. 102 (1): 87–90. PMID 3343573.
  3. ↑ Woods JE (1987). "Extended use of sodium tetradecyl sulfate in treatment of hemangiomas and other related conditions". Plast Reconstr Surg. 79 (4): 542–9. PMID 3823245.
  4. ↑ Empty citation (help)
  5. ↑ "http://www.ismp.org". External link in |title= (help)

{{#subobject: 

 |Page Name=Sodium tetradecyl sulfate
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject: 

 |Label Page=Sodium tetradecyl sulfate
 |Label Name=Sodium tetradecyl sulfate11.png

}}

{{#subobject: 

 |Label Page=Sodium tetradecyl sulfate
 |Label Name=Sodium tetradecyl sulfate11.png

}}

Retrieved from "https://www.wikidoc.org/index.php?title=Sodium_tetradecyl_sulfate&oldid=1071083"